This clinical trial is focused on studying mild cognitive impairment and dementia, which are conditions that affect memory and thinking skills. The study will use a treatment called Flortaucipir, also known by its code name LY3191748. Flortaucipir is a solution for injection that helps in imaging the brain to detect abnormal protein deposits associated with these conditions. The purpose of the study is to evaluate how well this imaging technique, known as tau PET, can improve the accuracy of diagnosing these memory-related conditions and enhance patient care.
Participants in the study will undergo a tau PET scan, which is a type of imaging test that helps doctors see changes in the brain. This test will be compared to other diagnostic methods to see if it provides better information. The study will look at how the use of tau PET affects the diagnosis, the confidence of doctors in their diagnosis, and the management of the patient’s condition. It will also assess how this imaging technique impacts the patient’s wellbeing, including their levels of anxiety and uncertainty.
The study will also explore how tau PET compares to new blood tests and artificial intelligence tools in diagnosing these conditions. The goal is to see if tau PET can offer a more reliable way to understand and manage mild cognitive impairment and dementia, ultimately improving the care and quality of life for patients with these conditions.
The Netherlands 
